The Image Analysis Group (IAG), known for its expertise in clinical trial imaging and AI-driven biomarkers, is broadening its footprint in the United States with a new office in Cambridge, Massachusetts. This strategic move places IAG’s business development and operations teams in close proximity to key biotechnology and pharmaceutical firms, enhancing the company’s ability to forge stronger partnerships and offer localized support for clinical trials throughout the region.
This expansion is set to bolster IAG’s involvement in various therapeutic areas such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic disorders. Operating from the Boston area will enable IAG to collaborate more effectively with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-focused development programs. The new office signifies IAG’s commitment to creating local employment opportunities, with plans to recruit staff in areas such as clinical imaging operations, data science, regulatory support, and business development over the coming 12 to 24 months.
IAG’s Cambridge office will enhance its comprehensive imaging services, which include consultation on clinical trial design, optimization of imaging protocols, centralized image analysis, and regulatory-compliant data delivery. By establishing itself within the dynamic Boston life-sciences ecosystem, the company anticipates improved collaboration opportunities with biotechnology companies, pharmaceutical entities, academic institutions, and clinical research centers.
Globally, IAG facilitates clinical trials across North America, Europe, and the Asia-Pacific, partnering with pharmaceutical, biotechnology, and medtech companies as well as CROs for multi-center studies. Its international operations aim to ensure standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across global trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). The firm supports pharmaceutical, biotechnology, and medical technology companies by providing imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis with centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.